The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Apax opts against lifting offer; DCI enters loan deal

Fri, 09th Feb 2024 18:53

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

RTW Biotech Opportunities Ltd - New York-based investment firm focused on the life sciences sector - Notes announcement by Kyverna Therapeutics regarding its pricing of a USD319 million initial public offering, upsized USD137 million above its initial estimate last week. Kyverna is a clinical-stage cell therapy biopharma company, in which RTW initially invested through a Series B funding round in early 2022. On the first day of trading, Kyverna's share price traded up by 36% to close at USD30.00 per share.

----------

Symphony Environmental Technologies PLC - Hertfordshire-based firm developing technology to make plastic biodegradable - Says that the General Court of the European Union found that the defendants didn't exceed "the limits of their discretion", so Symphony is not entitled to compensation. However, Symphony explains that the judgement was not an assessment of the effectiveness of the d2w technologies. Adds that the court didn't include further studies that have supported the technology, as well as the distinction between oxo-biodegradable and oxo-degradable plastics. Says that d2w technology has not been widely used in the EU for several years, and the lengthy legal process and judgment has "very little effect" on existing business.

----------

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Notes dispute with Stalicla SA, its partner in autism spectrum disorder and other neurodevelopmental disorders. Explains that in October 2022, Evgen licensed the rights for its lead asset, SFX-01, to Stalicla for up to USD160.5 million in milestone payments. An initial USD500,000 was paid upfront with the next anticipated payment of USD500,000 due on completion of the Evgen-sponsored human volunteer Phase 1 study. Evgen, having completed a Phase 1b study, believes the next payment is now due, and says it has formally implemented the dispute resolution process. It had not anticipated any milestone payments from Stalicla in its financial forecasting, and its cash runway remains unchanged.

----------

Substrate Artificial Inteligence SA - Madrid-based incubator of companies providing artificial intelligence products and services in fintech, agritech, energy, human resources, and health sectors - Signs investment deal with Indico Investments and Management SL, for a maximum of EUR2.0 million. The investment commitment, which expires on February 7, relates to the company's Class A shares. It will be carried out in tranches of EUR500,000, with a discount of 10%.

----------

DCI Advisors Ltd - British Virgin Islands-based real estate investment company - Says it has entered another loan agreement for EUR350,000 with a shareholder to provide additional working capital. The shareholder providing this loan previously entered into a loan agreement with DCI Advisors for EUR350,000 last October. To date, DCI has received seven loans of EUR350,000 each and two loans from funds managed by a single shareholder amounting to USD330,000 in aggregate.

----------

Apax Global Alpha Ltd - Guernsey-based investor in technology, services, healthcare, internet and consumer - Confirms that the offer of 120 pence in cash per Kin and Carta PLC share is final and will not be increased. In December, Apax said that a 'no increase statement' relating to its own offer price was no longer in effect and had been set aside, after Kin & Carta accepted an offer of 130p per share from Valtech, a company controlled by funds advised by London-based BC Partners LLP.

----------

Sutton Harbour Group PLC - Plymouth, England-based waterfront regeneration specialist - Notes press statement made by Plymouth City Council on Thursday, and confirms that it has received a letter from the Council alleging a breach of the Plymouth City Airport lease. Says that it is considering, in conjunction with its advisers, the contents of the letter, and will provide an update in due course.

----------

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
7 Aug 2019 11:47

Evgen Pharma Gets European Patent Covering Composition Of SFX-01

(Alliance News) - Evgen Pharma PLC on Wednesday said it has secured further intellectual property rights in Europe for SFX-01.The drug development company, focused on breast cancer and said

Read more
5 Aug 2019 11:45

Evgen Pharma To Collaborate With King's College And British Heart

(Alliance News) - Evgen Pharma PLC said Monday that it backs the new research collaboration between King's College London and the British Heart Foundation.The collaboration is how - - a

Read more
18 Jul 2019 13:00

Evgen Pharma Outlook Confident As Progresses Programmes Development

(Alliance News) - Evgen Pharma PLC on Thursday expressed confidence for the year ahead as it continued to progress on the development of its clinical programmes.Ahead of its annual general

Read more
13 Jun 2019 12:21

Evgen Pharma Annual Loss Fractionally Wider On Small Expense Rise

(Alliance News) - Evgen Pharma PLC on Thursday said its loss marginally widened in its most recent financial year due to slightly higher expenses as drug development continues.Clinical drug

Read more
13 Jun 2019 09:03

Evgen Pharma losses edge wider on higher costs

(Sharecast News) - Evgen Pharma on Thursday reported a slightly widened annual loss due to a cost increase, with its results in line with expectations as its drugs remain in the development stage.

Read more
17 Apr 2019 13:17

Evgen Pharma Raises GBP5 Million Via Share Placing (ALLISS)

LONDON (Alliance News) - Evgen Pharma PLC said Wednesday it raised GBP5.0 million via issue of shares in an oversubscribed placing.The clinical stage drug development company issued 13.1 at

Read more
25 Mar 2019 10:23

Good Headline Results From Evgen Pharma Breast Cancer Study Of SFX-01

LONDON (Alliance News) - Evgen Pharma PLC on Monday announced positive headline results from its phase two Stem trial of SFX-01 in advanced breast cancer.Shares in the clinical-stage drug -

Read more
18 Mar 2019 11:10

Evgen Pharma Expects STEM Trial Read-Out Next Week

LONDON (Alliance News) - Evgen Pharma PLC on Monday said it expects the final read-out of its STEM trial in metastatic breast cancer to be announced early next week, in line with its guidance of

Read more
5 Mar 2019 11:35

Study Of Evgen Pharma's SFX-01 Multiple Sclerosis Drug Shows Promise

LONDON (Alliance News) - Clinical stage drug developer Evgen Pharma PLC on Tuesday said a study has been published showing that its lead product, SFX-01, reduces residual disability in a model of

Read more
5 Feb 2019 09:18

Evgen Pharma Finishes Patient Recruitment For Stroke Treatment Trial

LONDON (Alliance News) - Evgen Pharma PLC on Tuesday said it has completed patient recruitment in its SAS phase II trial for proposed treatment SFX-01.SFX-01 is a planned treatment for a an

Read more
12 Dec 2018 11:11

Evgen Pharma Interim Loss Widens As It Progresses New Drug Trials

LONDON (Alliance News) - Evgen Pharma PLC on Wednesday said its interim loss widened slightly for its most recent half as it focuses on advancing trials.For the six month to September 30, a

Read more
12 Dec 2018 10:10

Evgen Pharma's loss widens amid excitement over cancer treatment

(Sharecast News) - Evgen Pharma's shares stumbled on Wednesday after its interim loss before tax expanded, though the company was "delighted" by progress in treatment developments.

Read more
23 Oct 2018 12:55

David And Monique Newlands Build 5% Stake In Evgen Pharma (ALLISS)

LONDON (Alliance News) - Evgen Pharma PLC said Tuesday that David and Monique Newlands now own 5.06% stake in the company.The Newlands' holding before the transaction, if any, was not

Read more
18 Oct 2018 10:26

Evgen Pharma Raises GBP750,000 Via Share Placing (ALLISS)

LONDON (Alliance News) - Evgen Pharma PLC said Thursday it raised GBP750,000 via share placing.The company issued 5.6 million shares at 13.5p. Shares in the drug development company were at

Read more
11 Sep 2018 12:51

Tueday broker round-up

(Sharecast News) - JD Wetherspoons: Berenberg upgrades to buy with a target price of 1,450p.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.